相关实验视频

Updated: Feb 28, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

评估mTOR,NFκB和BCL-2抑制剂活性在微散大B细胞淋巴瘤细胞上的体外检测

Agata Majchrzak¹, Sylwia Mańka^1,2, Barbara Cebula-Obrzut^1,2

¹Department of General Hematology, Copernicus Memorial Hospital, 93-513 Lodz, Poland.

Current issues in molecular biology

|February 27, 2026

概括

针对BCL-2,mTOR和NFκB的新型药物组合在扩散型大B细胞淋巴瘤 (DLBCL) 中表现有前途. 研究表明,特定的药物配对是有效的,为DLBCL治疗需要进一步的体内调查.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

扩散型大B细胞淋巴瘤 (DLBCL) 是一种具有特征NFkB通路干扰和BCL-2/mTOR蛋白脱调的侵袭性淋巴瘤,导致抑制的亡.
目前的治疗策略针对这些途径,但单一治疗可能不足,需要组合方法.

研究的目的:

评估针对单独或组合的BCL-2,mTOR和NFκB的新型抑制剂对代表ABC和GCB亚型的DLBCL细胞系的疗效.

主要方法:

在体外研究中使用了Riva (ABC亚型) 和Toledo (GCB亚型) DLBCL细胞系.
测试了三种新药:AZD2014 (mTOR 抑制剂),IMD-0354 (NFκB 抑制剂) 和ABT-199 (BCL-2 抑制剂).
药物被用作单疗法,双疗法和三药组合治疗.

主要成果:

在Riva细胞中,ABT-199显示出最强的单一疗法效果. 结合AZD2014+ABT-199和ABT-199+IMD0354的组合同样有效,但三种药物组合没有额外的益处.
在托莱多细胞中,单疗法没有显著差异. AZD2014+ABT-199组合是最有效的,三药组合没有增强这种效果.

结论:

BCL-2和mTOR抑制剂在DLBCL治疗中显示出潜力,特别是在特定的组合中.
需要进一步的体内研究来验证这些发现,并评估这些药物组合对DLBCL的ABC和GCB亚型的治疗潜力.

关键词:

这是一种BCL-2抑制剂.NFκB 抑制剂的使用扩散大的B细胞淋巴瘤.这是一种mTOR抑制剂.

更多相关视频

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs

Published on: December 27, 2016

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...